Navigation Links
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Date:1/9/2008

and Director, Clinical Investigation and Translational Research in the Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center and a principal investigator for this trial. "There have been no new approved therapies in relapsed/refractory Hodgkin lymphoma for decades. As epigenetics is thought to play a role in lymphoma, this clinical study will help build an understanding of the role of HDAC inhibitors and demethylating agents in the treatment of non-Hodgkin and Hodgkin lymphoma."

Encouraging anti-tumor activity has been demonstrated in a Phase 2 clinical study of MGCD0103 as a single agent in the relapsed or refractory Hodgkin lymphoma patient population. Data from the ongoing study, presented at the American Society of Hematology (ASH) annual meeting last month, reported an objective complete and partial response (CR and PR) rate of 38 percent and a disease control rate of 43 percent in 21 evaluable patients in the 110mg cohort. Eighty-six percent of patients who had CT scans experienced a reduction in tumor size, with 57 percent experiencing a tumor reduction of greater than 30 percent. The two CR patients have a preliminary progression-free survival (PFS) of 14 and nine months at the time of analysis, and the range of PFS from the responder group is 56 to greater than 396 days. Adverse events associated with MGCD0103 administration of grade 3 or higher included pneumonia (15 percent), thrombocytopenia (12 percent) and fatigue (nine percent). Dose modification was effective in many of these patients.

About MGCD0103

MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor. The compound is currently in one Phase 1 combination clinical trial with Taxotere(R) for solid tumors, two Phase 1/2 combination trials with Vidaza(R) for hematological malignancies and with Gemzar(R) for pancreatic cancer; and five Phase 2 clinical trials in hematological malignancies.

MGCD0103 has received orphan drug designation from the U.S. Food a
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
5. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... YORK , Sept. 2, 2015 About ... is a malignant condition characterized by increased production of ... affects B-lymphocytes and then it can spread to other ... at later stages because of the slow buildup of ... the malignancy spreads to the spleen, liver, and lymph ...
(Date:9/2/2015)... Sept. 2, 2015 Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ... Affairs in China (Basel, Switzerland - November 26-27, 2015)" ... provide a detailed overview of the key areas of pharmaceutical ... Hong Kong , Macau and ... - All important aspects of gaining and maintaining a ...
(Date:9/2/2015)... Miss. , Sept. 2, 2015   Gulf Coast Tattoo ... removal services with the cutting-edge Astanza Duality laser in ... unwanted ink erase their tattoo regret and take back control of ... but extends its services to Biloxi ... region. "With tattoo regret being as prevalent as it ...
Breaking Medicine Technology:Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2
... ALTO, Calif., April 25, 2012  Varian Medical Systems (NYSE: ... quarter of fiscal year 2012 with net earnings of $0.94 ... share in the second quarter of fiscal year 2011.  The ... a $2.5 million or $0.02 per diluted share restructuring charge ...
... AKRON, Ohio, April 25, 2012  Researchers, health care ... for the inaugural National Conference on Value-driven Engineering ... assembled by the Austen BioInnovation Institute in Akron ... Foundation. Experts from some of the nation,s leading ...
Cached Medicine Technology:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012 2Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012 3Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012 4Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012 5Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012 6Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012 7Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012 8Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering 2Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering 3Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering 4
(Date:9/3/2015)... , ... September 03, 2015 , ... At Renew Man™, ... dissatisfied with the traditional health care model, where the primary care physician dictates and ... who want to become educated about their health issues and empowered to choose their ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... Bob Anders and Kelley Chapman will be joining the company’s executive leadership team ... Anders has over 30 years’ experience in healthcare product and project management. He ...
(Date:9/2/2015)... ... September 03, 2015 , ... Leah ... among the most influential leaders in healthcare, will offer the keynote address at ... place October 15-16, 2015, in Palm Harbor, Florida, at the Innisbrook Resort and ...
(Date:9/2/2015)... ... ... Chris Harrison of Harrison’s Footwear of Poulsbo announces the launch of his ... “We have a lot of repeat customers, and many of them drive quite a ... given them the convenience of ordering from home.” , Harrison’s Footwear has gained a ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Telehealth represents ... Well Corp., contracted to handle the telehealth services of more than 12 Blues plan ... and Blue Shield Plans takes a look this growing trend, interviewing executives at Capital ...
Breaking Medicine News(10 mins):Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3
... had today undergone treatment at the All India Institute of ... to him explained that Gogoi, who had returned to India ... taken to AIIMS as he had complained of uneasiness. ... said that he was suffering from dehydration. The Chief Minister ...
... Zanzibar, a semi-autonomous island in Tanzania have multiplied ... to control the outbreak //of bird flu on the island. ... into Zanzibar from mainland Tanzania, were destroyed last ... of them were facing prosecution after they failed to ...
... From the research results of Dr Andrew Wakefield, their seems to ... autism related bowel // diseases – Lancet published in 1998 says. ... the MMR vaccinated children need to face a charge of professional ... people revealed nearly 92% of children in the year 1995-96 and ...
... is found that the survival rate of Hodgkin’s disease (HD) ... the study were published in the journal Cancer. //It revealed ... the best prognosis. There were significant differences existed between the ... of the lymphatic system of the body, which includes lymph ...
... people have succumbed to AIDS in Sagar district of Madhya Pradesh ... ,Of the 53 infected with the Human Immunodeficiency Virus (HIV) ... of full blown AIDS, including one woman, 16 men and two ... were detected in the district in March, 10 HIV cases came ...
... Organization said on Monday that it was setting up ... Chinese government //in fighting diseases like severe acute respiratory ... joint statement from the WHO and China's Ministry of ... Tuesday at the Center for Disease Control and Prevention ...
Cached Medicine News:Health News:HD Type Plays an Important Role in the Survival of the Patient 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: